OncologyConsults






All Modules

A Focus on Supportive Care:
Strategies to Improve Nausea and Vomiting in Cancer Patients
CME Credits: 0.5
Chemotherapy-induced nausea and vomiting (CINV) is a serious problem that can negatively impact a cancer patient’s quality of life and affect the timely deliver and ability to give the most effective doses of the chemotherapy treatment.
Faculty: Susan Urba, MD Expires: 11/19/2018


Addressing Unmet Needs in Mesothelioma:
Evaluating the Role of Angiokinase Inhibitors
CME Credits: 0.5
Malignant pleural mesothelioma (MPM) is a relatively rare but serious malignancy that arises from the mesothelial surfaces of the pleural cavity. Most cases of MPM are associated with workplace exposure to high levels of asbestos, with the onset of cancer typically occurring 20 to 50 years after asbestos exposure.
Faculty: Patrick Forde, MBBCh Expires: 03/5/2019


Advances in Soft Tissue Sarcoma CME Credits: 1.0
Soft-tissue sarcomas (STSs) are a heterogeneous collection of rare tumors. As such, they can arise within any site of the body, including the extremities, trunk, retroperitoneum, and head and neck.
Faculty: Nita Ahuja, MD, Chung-Shien Lee, PharmD, BCPS, BCOP , and Bradley N. Reames, MD, MS Expires: 12/15/2018


Appropriate Use of Immune Therapy to Treat Head and Neck Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: David S. Ettinger, MD Expires: 9/7/2018


Considerations for Using Immune Therapy in Treating Metastatic Non-Small Cell Lung Cancer CME Credits: 0.5
Recent advances in immune therapy for patients with non-small cell lung cancer (NSCLC) have taken a long-awaited step forward and shifted the standard of care of patients with advanced and metastatic disease.
Faculty: David S. Ettinger, MD Expires: 11/19/2018


Considerations for Use of Immune Therapy to Treat Metastatic Colorectal Cancer CME Credits: 0.5
Colorectal cancer (CRC) is a leading cause of cancer-related deaths with poor 5-year survival rates for patients with metastatic disease. Patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) are a distinct biomarker-defined population who may benefit less from conventional therapy compared with patients with MMR-proficient/microsatellite stable mCRC.
Faculty: Dung T. Le, MD Expires: 05/30/2020


Immunotherapy for the Treatment of Non-Small Cell Lung Cancer CME Credits: 1.0
Lung cancer is the leading cause of cancer-related mortality in the world, and approximately 85% of all lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC).
Faculty: Jarushka Naidoo and Beatriz Wills Expires: 5/3/2020


Integrating Immunotherapy into SCCHN Care: Implications for the Multidisciplinary Oncology Care Team CME Credits: 0.5
While the US Food and Drug Administration approval of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit for patients with head and neck cancer.
Faculty: Young Jun Kim, MD, PhD Expires: 6/15/2020


Metastatic Melanoma: Managing Benefit and Risk with the New Systemic Therapies CME Credits: 0.5
Melanoma is one of the most lethal human cancers and has historically been among the most resistant to contemporary chemotherapeutic approaches. It is the most serious form of skin cancer and has the highest mortality rate of all skin cancer types, leading to a rapid decline in the health in people who often are in the prime of life.
Faculty: William Sharfman, MD, FACP Expires: 5/20/2018


The Emerging Role of Immunotherapy in Treating Patients with Triple-Negative Breast Cancer CME Credits: 0.5
Triple negative breast cancer (TNBC) is a biologically heterogeneous disease that accounts for about 15% of all breast cancers. Unlike luminal breast tumors, which express the estrogen receptor and/or progesterone receptor, and human epidermal growth factor receptor-2-overexpressing (HER-2+) breast cancers, TNBC does not express a prototypical target for therapy that has been clinically validated.
Faculty: Leisha A. Emens, MD, PhD Expires: 3/12/2019